Stromal Reprogramming through Dual PDGFRα/β Blockade Boosts the Efficacy of Anti-PD-1 Immunotherapy in Fibrotic Tumors.
Takahiko AkiyamaTadahito YasudaTomoyuki UchiharaNoriko Yasuda-YoshiharaBenjy Jek Yang TanAtsuko YonemuraTakashi SembaJuntaro YamasakiYoshihiro KomoharaKoji OhnishiFeng WeiLingfeng FuJun ZhangFumimasa KitamuraKohei YamashitaKojiro EtoShiro IwagamiHirotake TsukamotoTerumasa UmemotoMari MasudaOsamu NaganoYorifumi SatouHideyuki SayaPatrick Boon-Ooi TanHideo BabaTakatsugu IshimotoPublished in: Cancer research (2023)
Stromal targeting with PDGFRα/β dual blockade reverses the immunosuppressive microenvironment and enhances the efficacy of immune checkpoint inhibitors in fibrotic cancer. See related commentary by Tauriello, p. 655.